429 related articles for article (PubMed ID: 35144680)
1. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.
Mehani B; Asanigari S; Chung HJ; Dazelle K; Singh A; Hannenhalli S; Aldape K
Acta Neuropathol Commun; 2022 Feb; 10(1):19. PubMed ID: 35144680
[TBL] [Abstract][Full Text] [Related]
2. Correlation of immune phenotype with IDH mutation in diffuse glioma.
Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
[TBL] [Abstract][Full Text] [Related]
3. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
4. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
5. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.
Wang Z; Liu X; Wang Z; Bao Z; Zhang W; Zhang C; Jiang T
Curr Mol Med; 2018 Mar; 17(7):518-526. PubMed ID: 29437008
[TBL] [Abstract][Full Text] [Related]
7. A machine learning analysis of a "normal-like" IDH-WT diffuse glioma transcriptomic subgroup associated with prolonged survival reveals novel immune and neurotransmitter-related actionable targets.
Nguyen HD; Allaire A; Diamandis P; Bisaillon M; Scott MS; Richer M
BMC Med; 2020 Oct; 18(1):280. PubMed ID: 33059718
[TBL] [Abstract][Full Text] [Related]
8. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
Hu X; Martinez-Ledesma E; Zheng S; Kim H; Barthel F; Jiang T; Hess KR; Verhaak RGW
Neuro Oncol; 2017 Jun; 19(6):786-795. PubMed ID: 28340142
[TBL] [Abstract][Full Text] [Related]
9. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
10. A map of the spatial distribution and tumour-associated macrophage states in glioblastoma and grade 4 IDH-mutant astrocytoma.
Yin W; Ping YF; Li F; Lv SQ; Zhang XN; Li XG; Guo Y; Liu Q; Li TR; Yang LQ; Yang KD; Liu YQ; Luo CH; Luo T; Wang WY; Mao M; Luo M; He ZC; Cao MF; Chen C; Miao JY; Zeng H; Wang C; Zhou L; Yang Y; Yang X; Wang QH; Feng H; Shi Y; Bian XW
J Pathol; 2022 Oct; 258(2):121-135. PubMed ID: 35723032
[TBL] [Abstract][Full Text] [Related]
11. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
[TBL] [Abstract][Full Text] [Related]
12. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Chen SC; Lo CM; Wang SH; Su EC
BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
14. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
[TBL] [Abstract][Full Text] [Related]
15. Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade.
Grewal EP; Richardson LGK; Sun J; Ramapriyan R; Martinez-Lage M; Miller JJ; Cahill DP; Choi BD; Curry WT
Neurosurg Focus; 2024 Feb; 56(2):E2. PubMed ID: 38301244
[TBL] [Abstract][Full Text] [Related]
16. High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis.
Zheng L; Zhang M; Hou J; Gong J; Nie L; Chen X; Zhou Q; Chen N
Neuropathology; 2020 Dec; 40(6):599-605. PubMed ID: 32761642
[TBL] [Abstract][Full Text] [Related]
17. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
Macaulay RJ
Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
[TBL] [Abstract][Full Text] [Related]
19. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
20. IDH clonal heterogeneity segregates a subgroup of non-1p/19q codeleted gliomas with unfavourable clinical outcome.
Luo S; Zhu S; Liao J; Zhang Y; Hou X; Luo T; Zhao E; Xu J; Pang L; Liang X; Xiao Y; Li X
Neuropathol Appl Neurobiol; 2021 Apr; 47(3):394-405. PubMed ID: 33098109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
